PTU - Polskie Towarzystwo Urologiczne
list of articles:

Article published in Urologia Polska 1999/52/3.


Barbara Pieńkowska-Grela 1, Roman Sosnowski 2, Tomasz Demkow 2
1 Samodzielna Pracownia Cytogenetyki Centrum Onkologii w Warszawie
Kierownik pracowni: dr n. med. B. Pieńkowska-Grela
2 Klinika Nowotworów Układu Moczowego Centrum Onkologii w Warszawie
Kierownik kliniki: dr n. med. T. Demkow


testis testicular germ cell tumor chromosomal aberations isochromosome i(12p) ? results of treatment


Malignant transformation may by caused by gene deregulation resulting from
specific chromosomal rearrangements. Adult testicular germ cell tumors (TGCT)
for clinical and pathological reasons divided in seminoma (SE) and non-
seminoma (NS), arise by transformation of germ cell. In most patients these
tumors are cured using cisplatin-based Combination chemotherapy. Important
steps in the TGCT oncogenesis seem to be polyploidization and formation of
the i(12p) marker chromosome. Cytogenetic studies have shown that
multiplication of 12p manifested in the i(12p) marker (in 80% of cases) or in
aberrant markers containing chromosome 12p material constitutes a uniąue
change in GCT which can be used as diagnostic marker. The consistent
amplification of critical 12p region in all histological subtypes of TGCT indicates
that this genetic abnormality could play an critical role in the ethiology, progres-
sion or prognosis of these tumors.


  1. [1] Atkin, N: B.: High chromosome number of seminomała and malignant teratoma
  2. of the testis: a review of data 103 tumours. Br. J. Cancer 1973, 28, 275-278.
  3. [2] Atkin, N. B., Baker, M. C: i(12p): Specific chromosomal marker in seminoma and
  4. malignant teratoma of the testis?. Cancer Genet. Cytogenet. 1983,10,199-204.
  5. [3] Bosi, G. ]., Geller, N. L., Bajorin, D., Leitner, S. R, Yagoda, A., Golbey,
  6. R. B., Scher, H., Yogelzang, N. ]., Auman ]., Carey, R., et al: A random-
  7. ized trial ofetopside + cisplatin versus vinblastine + bleomycin + cispaltin + cyclo-
  8. phosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J.
  9. Clin. Oncol. 1988, 6,1231-1238.
  10. [4] Bosi, G. }., et al.: Clinical relevance of the i(12p) marker chromosome in germ cell
  11. tumors.}. Natl. Cancer Inst. 1994, 86, 349-355.
  12. [5] Bosi, G. J., et al.: Isochromosome of the short arm of chromosome 12: Clinically
  13. useful markers for male germ cell tumors. J. Nat. Cancer Inst. 1989, 81, 1874-
  14. 1878.
  15. [6] Bosi, G. J., et al.: The use of tumor markers in germ cell malignancies. Hematol.
  16. Oncol. Clin. North Am. 1994 , 8, 573-587.
  17. [7] Brecher, R., et al.: Use of fluorescence in situ hybridization and comparative gen-
  18. omic hybridization in the cytogenetic analysis of testicular germ cell tumors and
  19. uveal melanoma. Cancer Genet. Cytogenet. 1997, 93, 22-28.
  20. [8] Castedo, S. M., de Jong, Oosterhuis, ]. W., Seruca, R., et al.: Chromosom-
  21. al changes in human primary testicular nonseminomatous germ cell tumors. Can-
  22. cer Res. 1989, 49, 5696-5701.
  23. [9] Einhorn, L. H., Williams, S. D., Loehrer, P. ]., Birch, R., Drasga, R.,
  24. Omura, G., Greco, F. A.: Evaluation of optimal duration of chemotherapy in
  25. fanorable-prognosis disseminated germ. cell tumors: a Southeastern Cancer Study
  26. Group protocol. J. Clin. Oncol. 1989, 7, 387-391.
  27. [10] El-Naggar, A. K., Ro, J. Y., McLemore, D., et al.: DNA ploidy in testicular
  28. germ cell neoplasms. Histogenic and clinical implications. Am. J. Surg. Pathol.
  29. 1992,16, 611-618.
  30. [11] Ewing, J.: Teratoma testis and its deriimtes. Surg. Gynecol. Obstet. 1991, 12,
  31. 230-261.
  32. [12] Friedman, N. B.: The comparative morphogenesis of extragenital and gonadal
  33. tetretoid tumors. Cancer 1951, 4, 265-276.
  34. [13] Haim, S., Mitelman, F., et al.: Cancer Cytogenetics (Second edition). Willey-
  35. Liss, 1995, 69-140,166-179.
  36. [14] Uson, D. H., Bosi, G. J., Dimitrovsky, E., Chaganti, R. S.: Genetic analy-
  37. sis of germ cell tumors: current progress and future prospects. Hematol. Oncol.
  38. Clin. North. Am. 1991, 5,1271-1283.
  39. [15] Mostert, M. C, Verkerk, A. J.: Identification of the critical region of lip over-
  40. representation in TGCT of adolescent and adults. Oncogene. 1998,16,2617-2627.
  41. [16] Motzer, R. )., Cooper, K., Geller, N. L., Pfister, D. G., Lin, S-Y., Bajo-
  42. rin, D.~, Scher,- H. I., Herr, H., Fair, W., Morse, M., Sogani, P., Whitmo-
  43. re, W., Bosi, G. J.: Carboplatin + etoposide + bleomycin for patient with poor risk
  44. germ cell tumors. Cancer 1990, 65, 2465-2470.
  45. [17] Motzer, R. }., Geller, N., Bajorin, D., Scher, H., Tan, C, Hen, H., Soga-
  46. ni, P., Fair, W., Morse, M., Russo, P., Bosi, G.: Sahage chemotherapy for
  47. germ cell tumor patients: prior complete response as an important prognostic vari-
  48. able (Abstarct). Proc. Am. Soc. Clin. Oncol. 1990, 9,141.
  49. [18] Motzer, R. J., Rodriguez, E., Reuter, V. E? Bosi, G. J., Mazumdar, M.,
  50. Chaganti, R. K.: Molecular and cytogenetic studies in the diagnosis of patients
  51. with poorly differentiated carcinomas of unknown primary site. J. Clin. Oncol. 1995,
  52. 13, 274-282.
  53. [19] Nowel, P. C, Hungerford, D. A.: A minutę chromosome in human granulo-
  54. citic leukemia. Science 1960,132,1497.
  55. [20] Peltomaki, P., et al: Chromosome 12 in human testicular cancer: Dosage chan-
  56. ges and their parental origin. Cancer Genet. Cytogenet. 1992, 64, 21-26.
  57. [21] Pieńkowska, B., Grygalewicz, B., Witkowska, A.: Analiza występowania
  58. izochromosomu i(12p) w ludzkich guzach jąder przy zastosowaniu techniki fluore-
  59. scencyjnej hybrydyzacji in situ. Gin. Pol. 1997, 86, 274-251.
  60. [22] Pieńkowska, B., et al.: Analiza kariotypowa nowotworów jąder u człowieka.
  61. Nowotwory 1997, 47,108-119.
  62. [23] Rodriguez, E., Mathew, S., Router, V., et al.: Cytogenetic analysis of 124
  63. prospectwely ascertained male germ cell tumors. Cancer Res. 1992,52,2285-2291.
  64. [24] Summersgill, B., et al.: Molecular cytogenetic analysis of adult testicular germ
  65. cell tumours and identification ofregions of consensus copy number change. Br. J.
  66. Cancer 1998, 77, 305-313.
  67. [25] Tijo, J. Fl., Levan, A.: The chromosome number of man. Hereditas 1956,42,1-6.
  68. [26] Toner, G. C, Lin, S. Y., Geller, N. L., Ochoa, M., Bosi, G. J.: Survival and
  69. Prognostic featurs of extragonadal and poor risk nonseminomatous germ cell tu-
  70. mours. Proc. Am. Assoc. Cancer Res. 1989, 30, 259.
  71. [27] Vincent, T., et al.: Cancer: Principles and Practice of Oncology, Fourth Edition.
  72. 1993,1126-1132.
  73. [28] Zatoński, W., Tyczyński, J. (red.): Nowotwory złośliwe w Polsce w 1995. Za-
  74. kład Epidemiologii i Prewencji Nowotworów, Krajowy Rejestr Nowotwo-
  75. rów, 1998, Pracownia Poligraficzna Centrum Onkologii - Instytut.